Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
about
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.Current issues in oncology drug development, with a focus on Phase II trialsDesign and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.Patient education integrated with acupuncture for relief of cancer-related fatigue randomized controlled feasibility study.Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic review of clinical efficacy and quality assessment of reported trials.Randomized phase II trials: a long-term investment with promising returnsA single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.Innovative Clinical Trial Designs: Toward a 21st-Century Health Care SystemSequential design of phase II-III cancer trials.Targeting targeted agents: open issues for clinical trial designPhase II designs for anticancer botanicals and supplements.Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.Opportunities and challenges in using studies without a control group in comparative effectiveness reviews.Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies.Calculating sample size in trials using historical controls.Recommended changes to oncology clinical trial design: revolution or evolution?Reporting guidelines for oncology research: helping to maximise the impact of your research.
P2860
Q30437854-D1818E04-65F2-43DF-AEF3-1D9B218FC0B4Q33433456-D90FB981-A942-421E-AC0F-F1F8D5C2B97EQ33566395-872AD911-55EA-49BB-A010-5FE166033DC1Q33813448-3467AB80-F7E7-4A49-BD49-9E4794A4CB7AQ33942485-D80664A3-11E8-4E39-8F0C-2FCC9EE3CD38Q34193514-27D7009E-B9F8-4115-B6D5-C7BF8E3A8B39Q34340824-3FBD1CE5-0241-47B1-B668-D40EBC5AC4CBQ35115259-CBDB923C-8365-4B8C-BB72-102069D6F56EQ35597039-86B12F80-BA3D-45E5-8449-CC3C12DA7E0BQ35797280-B43F23E2-F7E9-4578-A9FE-B5508E34D772Q35940107-A91684A4-67F9-43A6-AD83-130A28104883Q37229389-BCCE1004-ABD7-4854-B600-27C0613FC69EQ37328889-F9AD00B0-68B7-44FC-94BB-063C4F44D972Q37458763-FBBDC722-9107-4460-9716-8E86CF806729Q38520010-DAF87982-F850-40E2-BA93-9FC7248639F8Q38737416-BD02E45C-986F-4008-AF07-D42567CD46E3Q40415839-D7ABF3E0-8F07-467C-9534-5F69B0E32C6EQ41852508-A9AC6D61-8AD9-44D9-AC6C-E1F56EECBE6DQ43140987-0342C845-4B25-48A5-9636-A6AFB728BAC3Q55076495-EFE9F406-5B9D-4264-A7FA-D2B51466B63B
P2860
Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Setting the bar in phase II tr ...... definitive phase III testing.
@ast
Setting the bar in phase II tr ...... definitive phase III testing.
@en
type
label
Setting the bar in phase II tr ...... definitive phase III testing.
@ast
Setting the bar in phase II tr ...... definitive phase III testing.
@en
prefLabel
Setting the bar in phase II tr ...... definitive phase III testing.
@ast
Setting the bar in phase II tr ...... definitive phase III testing.
@en
P2860
P1476
Setting the bar in phase II tr ...... definitive phase III testing.
@en
P2093
Howard I Scher
Vennus Ballen
P2860
P304
P356
10.1158/1078-0432.CCR-06-0909
P407
P577
2007-02-02T00:00:00Z